ClinicalTrials.gg
Not yet recruitingNCT07947290Updated Nov 18, 2026

Effects of PosBion® Supplementation on Intestinal Barrier Function in Adults With Irritable Bowel Syndrome

An interventional study of Lactiplantibacillus plantarum RS5- and RI11-Derived Postbiotic Metabolite Supplement in Irritable Bowel Syndrome (IBS), sponsored by My Myracle Sdn.Bhd. Not yet recruiting at 1 site in Malaysia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by My Myracle Sdn.Bhd · Not applicable, Interventional, and Supportive care

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Postbiotic metabolites produced by beneficial bacteria may influence inflammatory responses, mucosal immunity, and host physiological signalling. PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11, derived from Lactiplantibacillus plantarum RS5 and RI11, respectively.

This study will evaluate changes in a panel of salivary biomarkers following 12 weeks of PosBion® supplementation in adults with irritable bowel syndrome (IBS). The biomarkers include myeloperoxidase (MPO), zonulin, lipopolysaccharide (LPS), LPS-binding protein (LBP), cortisol, serotonin, secretory immunoglobulin A (sIgA), lactoferrin, interleukin-8 (IL-8), immunoglobulin E (IgE), immunoglobulin M (IgM), and immunoglobulin G (IgG).

The study will primarily evaluate changes in inflammatory activity, while additional biomarkers will be used to explore mucosal immune, neuroendocrine, immunoglobulin, microbial exposure, and barrier-related responses following supplementation.

Read the detailed description

Irritable bowel syndrome is a disorder of gut-brain interaction associated with complex alterations in immune activity, gastrointestinal physiology, microbial-host interactions, and mucosal function. Microbial metabolites derived from beneficial bacteria have received increasing attention because of their potential immunomodulatory, anti-inflammatory, antioxidant, and mucosal effects.

PosBion® is a commercially available dietary supplement containing LPM5 and LPM11, proprietary cell-free metabolite preparations derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. The finished preparations do not contain viable or inactivated bacterial cells.

Previous experimental investigations of RS5- and RI11-derived metabolites have demonstrated antimicrobial, antioxidant, immunomodulatory, and intestinal health-related activities. In particular, RI11-derived metabolites have been associated experimentally with modulation of inflammatory cytokines, antioxidant defence, and barrier-associated pathways.

The present study is designed as a prospective, single-arm, open-label interventional study to investigate longitudinal changes in salivary biomarkers following 12 weeks of PosBion® supplementation.

The principal biomarker of interest will be salivary IL-8 as a marker of inflammatory activity. Additional inflammatory markers will include MPO and lactoferrin. Mucosal and adaptive immune responses will be evaluated using sIgA, IgE, IgM, and IgG. Cortisol and serotonin will be investigated as neuroendocrine biomarkers.

Salivary zonulin, LPS, and LBP will also be assessed as exploratory biomarkers potentially related to microbial exposure and barrier-associated processes. Because these biomarkers are measured in saliva, they will not be interpreted as direct measurements of intestinal permeability.

Unstimulated saliva will be collected at baseline and after 4, 8, and 12 weeks of supplementation under standardized collection conditions. Biomarker concentrations will be quantified using commercially available validated assays according to the manufacturers' instructions.

The study is intended to provide mechanistic biomarker data on the biological responses associated with PosBion® supplementation rather than to evaluate changes in IBS symptom severity.

02

Conditions studied

  • Irritable Bowel Syndrome (IBS)

Keywords

  • Postbiotics
  • Lactiplantibacillus plantarum
  • inflammation
  • mucosal immunity
  • interleukin-8
  • secretory IgA
  • microbial exposure
03

In context

Irritable Bowel Syndrome

1,120 studies on the registry are indexed under Irritable Bowel Syndrome; 211 are open to participants now.

This study's planned enrollment of 55 is below the median of 70 across 899 interventional studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

My Myracle Sdn.Bhd is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older
  • Experienced one or more symptoms suggestive of irritable bowel syndrome (IBS) prior to enrolment
  • Willing to comply with interventional plan
  • Willing to give consent

Exclusion criteria

Exclusion Criteria:

  • History of chronic or serious medical conditions, including diabetes mellitus, cardiovascular disease, chronic kidney disease, cancer, or chronic respiratory disease
  • Current use of gastrointestinal health supplements
  • Current use of antibiotics or antiviral medications
  • Current use of probiotic, prebiotic, or postbiotic supplements
  • Major surgery within the previous 6 months.
  • Pregnant or lactating woman
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    PosBion® Supplementation

    Subjects will consume PosBion® for 12 consecutive weeks. Two sachets will be consumed daily, with one sachet taken after breakfast and one sachet after dinner. Saliva samples will be collected at baseline and Weeks 4, 8, and 12 for biomarker analysis.

    Dietary Supplement: Lactiplantibacillus plantarum RS5- and RI11-Derived Postbiotic Metabolite Supplement

Interventions

  • Dietary supplementLactiplantibacillus plantarum RS5- and RI11-Derived Postbiotic Metabolite Supplement

    PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11 derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. Each sachet contains 2,500 mg LPM5 and 2,500 mg LPM11. Subjects will consume two sachets daily for 12 weeks, with one sachet taken after breakfast and one after dinner. The finished preparations do not contain viable or inactivated bacterial cells.

    Also known as: PosBion®

06

What researchers measure

Primary outcomes

  1. Change in Salivary Interleukin-8 (IL-8) Concentration

    Salivary IL-8 concentration will be quantified using an enzyme-linked immunosorbent assay (ELISA). Changes over time will be evaluated, with the principal comparison between baseline and Week 12.

    Time frame: Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12

  2. Change in Salivary Myeloperoxidase (MPO)

    Salivary MPO concentration will be quantified using ELISA as a marker associated with neutrophil and inflammatory activity.

    Time frame: Baseline, Week 4, Week 8, and Week 12

  3. Change in Salivary Lactoferrin

    Salivary lactoferrin concentration will be quantified using ELISA as a marker associated with mucosal innate immune and inflammatory activity.

    Time frame: Baseline, Week 4, Week 8, and Week 12

  4. Change in Salivary Secretory Immunoglobulin A (sIgA)

    Salivary sIgA concentration will be quantified as a marker of mucosal immune activity.

    Time frame: Baseline, Week 4, Week 8, and Week 12

  5. Change in Salivary IgE

    Salivary IgE concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

    Time frame: Baseline, Week 4, Week 8, and Week 12

  6. Change in Salivary IgM

    Salivary IgM concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

    Time frame: Baseline, Week 4, Week 8, and Week 12

  7. Change in Salivary IgG

    Salivary IgG concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

    Time frame: Baseline, Week 4, Week 8, and Week 12

Secondary outcomes

  1. Baseline, Week 4, Week 8, and Week 12

    Salivary cortisol concentration will be quantified as a neuroendocrine biomarker associated with physiological stress responses.

    Time frame: Baseline, Week 4, Week 8, and Week 12

  2. Change in Salivary Serotonin

    Salivary serotonin concentration will be quantified as an exploratory neuroendocrine biomarker.

    Time frame: Baseline, Week 4, Week 8, and Week 12

Other outcomes

  1. Change in Salivary Zonulin

    Salivary zonulin will be quantified as an exploratory biomarker potentially associated with barrier-related processes. The measurement will not be considered a direct assessment of intestinal permeability.

    Time frame: Baseline, Week 4, Week 8, and Week 12

  2. Change in Salivary Lipopolysaccharide (LPS)

    Salivary LPS concentration will be evaluated as an exploratory marker of microbial exposure. Changes will not be interpreted as direct evidence of intestinal microbial translocation.

    Time frame: Baseline, Week 4, Week 8, and Week 12

  3. Change in Salivary LPS-Binding Protein (LBP)

    Salivary LBP concentration will be evaluated as an exploratory biomarker related to host responses to microbial products.

    Time frame: Baseline, Week 4, Week 8, and Week 12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual-level data underlying the reported study findings, together with relevant data dictionaries, may be made available to qualified researchers following publication.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Beginning approximately 6 months after publication of the primary study findings and available for up to 5 years.

Access criteria: Data may be provided to qualified researchers who submit a scientifically sound proposal. Requests will be reviewed by the principal investigator and/or study sponsor. Approved access may require a data-use agreement and secure transfer of de-identified data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 52 industry-sponsored interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 3 months is below that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Feb 15, 2027
CompletionEst.
Mar 15, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947290
Lead sponsor
My Myracle Sdn.Bhd
Collaborators
UCSI University
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Feb 15, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Chung Keat Tan, PhD
Contact
cktan.jsci@gmail.com
+60175063305

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion